Ramsay, Stattman, Vela & Price, Inc. Biogen Inc. Transaction History
Ramsay, Stattman, Vela & Price, Inc.
- $518 Million
- Q2 2024
A detailed history of Ramsay, Stattman, Vela & Price, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Ramsay, Stattman, Vela & Price, Inc. holds 7,545 shares of BIIB stock, worth $1.5 Million. This represents 0.34% of its overall portfolio holdings.
Number of Shares
7,545
Previous 7,545
-0.0%
Holding current value
$1.5 Million
Previous $1.63 Million
7.56%
% of portfolio
0.34%
Previous 0.32%
Shares
4 transactions
Others Institutions Holding BIIB
# of Institutions
1,050Shares Held
128MCall Options Held
1.22MPut Options Held
1.4M-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.29 Billion0.08% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$3.24 Billion2.78% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.88 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.1MShares$1.41 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.68MShares$1.13 Billion0.83% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $28.5B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...